83.5% ROCE, Zero Debt — What’s Really Driving P&G Health’s Numbers

P&G Health Ltd is one of India's largest VMS (Vitamins, Minerals, and Supplements) companies. Following a major global acquisition (P&G acquired Merck KGaA's Consumer Health segment for $4.2B in 2018), the company operates in the FMCG/Pharma hybrid space.

P&G Health Ltd Overview

Business: The company manufactures and sells pharmaceuticals, vitamins, and health supplements.

Its products are sold globally (in ~180 countries), but around 90% of revenue comes from India — meaning the company is heavily dependent on the Indian market.

Manufacturing:

The company has a single main manufacturing facility, located in Goa.

Distribution Shift:

In FY23, the company removed middlemen (C&F agents) from its supply chain and moved to a direct-distributor system. This made deliveries faster and improved product availability across both online and offline channels.

Important Key Metrics

Market Cap: The company's market cap is ₹10,115 Cr, placing it in the mid-cap healthcare category — neither small enough to carry very high risk, nor large enough that growth is fully capped.

Current Price vs 52-Week High/Low (₹6,088 | ₹6,975 / ₹4,700): The stock is trading roughly 12–13% below its 52-week high of ₹6,975, and has recovered significantly from its 52-week low of ₹4,700.

Stock P/E (30.4x): The sector median P/E is 33.86x, while peers such as Divi's (73.95x), Torrent (84.72x), and Mankind (47.11x) trade at much higher multiples. Compared to Sun Pharma (36.99x) and Cipla (33.32x) as well, PGHL's P/E of 30.4x sits below the sector median and below these listed peers.

Book Value (₹316): This puts the Price-to-Book ratio at ~19x. This can look high in isolation, but for asset-light MNCs this is common, since their real value sits in brands (Evion, Neurobion) rather than in heavy machinery or land.

Dividend Yield (2.54%): This functions similarly to passive income from a Fixed Deposit (FD) or regular savings instrument. A 2.5%+ dividend yield is on the higher side within the pharma/FMCG sector.

ROCE (83.5%) & ROE (61.6%):

ROCE (83.5%): For every unit of capital employed in the business, the company generates an 83.5% operating return.

ROE (61.6%): For every ₹100 of shareholder equity, the company generates ₹61.6 in net profit. For context, most Indian listed companies (the source cites ~99%) report ROCE/ROE below 20–25%.

Face Value (₹10.0): This is the reference value that would apply in the event of any future stock split.

Quarterly Results (Jun 2023 to Jun 2026) — Financial Analysis:

Top-Line (Sales Growth) — Turnaround Pattern (FY24 vs FY25-26):

In FY24 (Mar 2024 and Jun 2024), sales growth was negative, at -21.33% and -5.74% respectively — meaning growth had slowed sharply. Since Mar 2025, sales have shown a sharp recovery: Mar 2025 (+23.17%), Jun 2025 (+19.33%), Dec 2025 (+20.69%), and Mar 2026 (+19.12%) — double-digit growth across these quarters.

Cost Efficiency:

Material Cost %: This stood at 29–31% in FY23/24, and came down to 24.45% by Dec 2024 and 21.05% by Sep 2025. In the most recent quarter, however, this cost has risen again, reaching 25% in March 2026.

Employee Cost %: This was previously around 18–19%, and has since come down to a range of roughly 13.7%–16.5%.

This shows the company has generally managed to keep its expenses under control.

Operating Profit Margin (OPM) Expansion: OPM was 15% in Jun 2023, and reached 36–40% by Sep 2024 / Sep 2025 / Mar 2026. The average OPM currently sits in the 27–37% range.

Net Profit & EPS Trend:

EPS Expansion: Quarterly EPS rose from a low of ₹10.11 in Jun 2024 to a record ₹57.92 in Jun 2026.

Exceptional Item Note (Jun 2026): An exceptional income of ₹31.80 Cr in Jun 2026 contributed to Net Profit of ₹96 Cr and EPS of ₹57.92 for that quarter. Even excluding this exceptional item, the underlying operating profit trend remains consistently strong.

Zero Interest Expense: The company has reported ₹0 in interest expense across all recent quarters, consistent with a debt-free balance sheet.

P&G Health Ltd Balance Sheet Details

Equity Capital & Reserves:

Equity Capital (₹17 Cr): This has remained static and constant — the company has not diluted equity by issuing new shares.

Reserves (₹508 Cr – ₹522 Cr): Reserves peaked at ₹1,524 Cr in 2019–2020, and have since settled into the ₹500–700 Cr range. This is because the company distributes a large share of its net profit (90%+ payout) as dividends each year.

Borrowings & Debt Profile:

Short-term / Long-term Borrowings (₹0 – ₹9 Cr): The company is, in practical terms, debt-free. The ₹8–9 Cr in minor borrowings likely reflects lease or working-capital adjustments rather than conventional debt, and there is effectively no interest burden.

Fixed Assets & Gross Block:

Fixed Assets: These have declined from ₹144 Cr (2023) to ₹102 Cr (2026).

Cash & Cash Equivalents: The cash position has declined from ₹1,243 Cr (2019) to ₹185 Cr (2026). The cash pile was unusually high (₹1,240+ Cr) around the 2018–2019 P&G acquisition period. Over subsequent years, management has returned this excess cash to shareholders through special dividends and consistently high regular dividends. The current cash balance of ₹185 Cr covers the company's stated day-to-day operational needs and its dividend payments.

Cash Flow Statement (2015–2026)

Cash Flow From Operating Activities (CFO):

How much actual cash the business generates from operations is a critical metric for any company. CFO rose from ₹169 Cr (Mar 2025) to ₹338 Cr (Mar 2026) — roughly double. Additionally, nearly all of the Operating Profit (OP) reported in the P&L converts into actual cash. The CFO/OP conversion ratio has ranged between 97% and 102% over FY24–FY26, indicating clean accounting and high earnings quality.

Cash Flow From Investing Activities (CapEx):

How much the company reinvests into the business: CapEx was previously in the ₹35–52 Cr per year range, and has since come down to ₹21.7 Cr (Jun 2024), ₹8.5 Cr (Mar 2025), and ₹15.5 Cr (Mar 2026).

Cash Flow From Financing Activities (Dividends & Capital Return):

Where the cash goes: In Mar 2026, the company paid out ₹340 Cr in dividends (against CFO of ₹338 Cr) — the company distributes close to 100% of its operational and free cash flow to shareholders as dividends. Since the company carries no meaningful debt, debt repayment accounts for ₹0 in cash outflow.

Shareholding Pattern

Promoter Holding (51.82%): The parent MNC (The Procter & Gamble Company, USA) holds a constant 51.82% equity stake, with none of it pledged.

Institutional Holding (FIIs + DIIs, ~18.77% combined):

DII Trend: Domestic mutual funds/institutional investors increased their stake from 12.30% to 14.84% during FY24 (a period of distribution-transition and temporary slowdown), and have since brought it down to 12.44% amid the recent price run-up.

FII Trend: Foreign investor holding has stayed in a stable 6%–7.2% range.

Retail Shareholder Data:

While overall public holding has risen slightly (28.5% to 29.4%), the number of individual (retail) shareholders has declined noticeably:

Sep 2023: 57,919 shareholders

Jun 2026: 49,056 shareholders

This represents roughly 8,800+ fewer retail holders over this period, alongside holding shifting toward larger, more concentrated positions.

A quick note: This post is only meant to explain how I approach fundamental analysis, and I've only shared the numbers as they appear in public filings — this is not buy, sell, or hold advice for any company, nor is it a SEBI-registered research report. I am not a SEBI-registered advisor. Please do your own research and consult a qualified, SEBI-registered advisor before making any investment decisions.